Trial · NCT03552380
Adverse events156
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 156
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Adrenal insufficiency | Endocrine disorders | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 1 | 5 | 1 |
| other | Adrenal insufficiency | Endocrine disorders | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 1 | 7 | 1 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 1 | 5 | 1 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 0 | 7 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 1 | 5 | 4 |
| other | Anemia | Blood and lymphatic system disorders | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 2 | 7 | 2 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 1 | 5 | 1 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 1 | 7 | 1 |
| other | Creatinine increased | Investigations | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 1 | 5 | 2 |
| other | Creatinine increased | Investigations | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 1 | 7 | 1 |
| other | Dehydration | Metabolism and nutrition disorders | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 1 | 5 | 1 |
| other | Dehydration | Metabolism and nutrition disorders | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 0 | 7 | 0 |
| other | Diarrhea | Gastrointestinal disorders | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 1 | 5 | 3 |
| other | Diarrhea | Gastrointestinal disorders | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 0 | 7 | 0 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 2 | 5 | 3 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 1 | 7 | 1 |
| other | Edema limbs | General disorders | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 1 | 5 | 1 |
| other | Edema limbs | General disorders | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 1 | 7 | 1 |
| other | Eye infection | Infections and infestations | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 1 | 5 | 1 |
| other | Eye infection | Infections and infestations | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 0 | 7 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03552380/events